Premium
Older people with Type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies
Author(s) -
Hambling C. E.,
Seidu S. I.,
Davies M. J.,
Khunti K.
Publication year - 2017
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.13380
Subject(s) - medicine , sulfonylurea , dementia , diabetes mellitus , cohort , type 2 diabetes , kidney disease , insulin , population , interquartile range , endocrinology , disease , environmental health
Aim To evaluate potential overtreatment with sulfonylurea and insulin therapies amongst older people with Type 2 diabetes, including those with chronic kidney disease or dementia. Methods Using the ECLIPSE Live software tool, we developed a search to examine data on older people (age ≥ 70 years) with Type 2 diabetes, who were prescribed sulfonylurea or insulin therapies over the previous 90 days. Sixteen Norfolk general practices participated, representing a population of 24 661 older people, including 3862 (15.7%) with Type 2 diabetes. Of these, 1379 (35.7%) people were prescribed sulfonylurea or insulin therapies. Data extracted included age, sex, last recorded HbA 1c value, renal function and dementia codes. Results The median age of the study cohort was 78 years. A total of 644 people (47.8%) had chronic kidney disease (estimated GFR < 60 mL /min/1.73m 2 ) and 60 people (4.35%) had dementia. The median (interquartile range) HbA 1c concentration for the entire cohort was 58 (51–69) mmol/mol [7.5 (6.8–8.5)%], with no difference in median HbA 1c between those with or without either chronic kidney disease or dementia. In total, 400 older people (29.9%) had an HbA 1c concentration < 53 mmol/mol (7%), of whom 162 (12.1%) had HbA 1c < 48 mmol/mol (6.5%). Stratified by prescription for sulfonylurea, insulin or combined insulin and sulfonylurea therapies, 282 (35.2%), 93 (24.2%) and 25 people (16.3%), respectively, had HbA 1c < 53 mmol/mol (7.0%). Treatment to an HbA 1c target of < 53 mmol/mol (7.0%) was as prevalent in those with chronic kidney disease or dementia as in those without. Conclusion In the present cohort of older people with Type 2 diabetes prescribed sulfonylurea or insulin therapies, overtreatment was common, even in the presence of comorbidities known to increase hypoglycaemia risk.